Potential diabetes treatment selectively kills autoimmune cells from human patients; study confirms feasibility of human trials

In experiments using blood cells from human patients with diabetes and other autoimmune disorders, Massachusetts General Hospital (MGH) researchers have confirmed the mechanism behind a potential new therapy for type 1 diabetes.  A team led by Denise Faustman, MD, PhD, director of the MGH Immunobiology Laboratory, showed that blocking a metabolic pathway regulating the immune system specifically eliminated immune cells that react against a patient’s own tissues.  read more

Read the whole article on Harvard Science

More from Harvard Science